Approximately 40% of individuals with type 2 diabetes develop chronic kidney disease (CKD). Key to prevention of CKD in patients with type 2 diabetes is early awareness and identification of those at risk of rapid progression. CKD is characterized by progressive loss of kidney function, assessed by sequential estimated glomerular filtration rate (eGFR), a measurement that can vary between individuals. ...
Nephrology Times
Nephrology Times delivers the latest news in nephrological treatments and technologies with the goal of better informing care decisions and improving patient outcomes.
Advertisement
Latest News
Lori Hartwell, founder and president of the Renal Support Network, discusses the need for innovation for dialysis patients.
Differences in psoriatic arthritis symptoms are evident between patients with and without hyperuricemia.
Endovascular interventional procedures significantly increase the risk of gout flares in the postsurgical period.
Utilizing DECT showed that achieving a lower serum urate of <5.0 mg/dL leads to more extensive dissolution of MSU ...
Autoimmune hypothyroidism and autoimmune hyperthyroidism have a causal association with an increased risk of gout.
SGLT2i therapy is contraindicated in patients with type 1 diabetes mellitus (T1DM) who have CKD.
The actual burden of vaccine-preventable infections among recipients of solid organ transplants is unclear.
Community-acquired acute kidney injury (CA-AKI) is AKI that develops outside of the hospital setting.
A 2004 landmark study demonstrated an association between chronic kidney disease and an increased risk of CV events.
A recent study showed that patients with gout, CVD, CKD, and cancer had the highest risk of gout flares.
Advertisement
In Print
Coverage of the 2023 American Transplant Congress, managing gout in kidney transplant recipients, and more
Coverage of the European Renal Association 60th Congress, improved reimbursement for dialysis facilities, and more.
Conferences
The American Society of Nephrology's annual meeting to highlight the latest scientific and medical advances in the field
The National Kidney Foundation's premier educational event covering advancements in all subspecialties of nephrology
The joint annual meeting of the American Society of Transplantation and the American Society of Transplant Surgeons
The annual meeting hosted by the American Nephrology Nurses Association featuring clinical practice updates
Expert Columns
SGLT2i therapy is contraindicated in patients with type 1 diabetes mellitus (T1DM) who have CKD.
The first part of the dialysis moonshot is to prevent the need for dialysis.
When collections waver, a facility’s financial health teeters.
Measuring eGFR and UACR is a key component of guideline-directed medical therapy for patients with CKD from type 2 diabetes.
Advocacy for improved reimbursement is crucial to ensuring continued access to care.
The most important patients who should receive treatment with SGLT2 inhibitors are those with CKD and type 2 diabetes.
